Tenders Are Invited For Pharmaceutical Products – Amgros 2027 1.370.A in Denmark

Work Detail

Pharmaceutical Products – Amgros 2027 1.370.A. The Tender Number (Subcontract) Includes The Following Medicines: Atc Code: M05bx05 · Generic Name: Burosumab · Dispensing Form: Inj. Liquid, Solution · Strength: 10 Mg · Unit Value: 2.5 Mg · Quantity In Units: 432 ··· Atc Code: M05bx05 · Generic Name: Burosumab · Dispensing Form: Inj. Liquid, Solution · Strength: 20 Mg · Unit Value: 2.5 Mg · Quantity In Units: 1896 ··· Atc Code: M05bx05 · Generic Name: Burosumab · Dispensing Form: Inj.Liquid, Solution · Strength: 30 Mg · Unit Value: 2.5 Mg · Quantity In Units: 3660. Each Tender Number Is Considered An Independent Sub-Contract And Is Offered Independently Of The Other Tender Numbers. A Supplier Can Thus Choose To Make An Offer For One, Several Or All Tender Numbers, And Allocation Is Made Separately For Each Individual Tender Number. A Supplier Can Thus Be Awarded One, Several Or All Partial Contracts. Reference Is Made To The Tender Conditions, Including The Submission Of Tenders Under The Individual Tender Numbers. Under The Designation Quantity In Units Above, An Estimated Consumption Of The Medicines Under The Tender Number Is Given, But The Real Consumption May Differ Significantly From There. The Suppliers Must Anticipate This. The Background For This Is That These Are Medicines For Patient Treatment In Public Hospitals, Where The Patients Needs Must Be Met. The Medicines On Offer Are Also Subject To One Or More Recommendations And/Or Treatment Guidelines From The Medical Council, And The Consumption Of The Various Medicines Can Be Significantly Affected By This. For A More Detailed Description, Please Refer To The Tender Conditions And The Framework Agreement. The One Below Under Section 5.1.5 Maximum Value Of The Partial Contract Is Calculated As A Share Of 100% Of The Estimated Total Value Of All Partial Contracts Listed In Section 2.1.3. This Is Because All The Medicines On Offer Are Covered By One Or More Recommendations And/Or Treatment Guidelines From The Medical Council, Which Assesses Which Of The Medicines On Offer Are Recommended For Treatment For Different Patient Populations, Possibly So That Certain Medicines Are Considered Equal Possible First Choices, Recommended For Use In Priority Order Or The Like. The Medical Councils Assessment Can Therefore Have A Significant Impact On Which Of The Medicines On Offer Are Used Within Different Therapy Areas And Patient Populations, And The Consumption Of The Individual Medicines Can Also Depend On Current Contract Prices. This Means That It Is Not Possible At The Time Of The Tender To Estimate Which Medicines Will Primarily Be Used During The Term Of The Framework Agreement, And It Is Possible That The Use Of The Medicines May Change Significantly During The Term Of The Framework Agreements, Including In Particular By Approval Of New Indications For The Individual Medicines, Changed Treatment Of One Or More Patient Populations And The Like. Determining The Maximum Value Of The Individual Subcontracts As A Share Of The Total Estimated Quantity Of All Subcontracts Aims To Ensure That Each Of The Concluded Framework Agreements Can Be Used As Necessary In

Contact Information